| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
51,640,000 |
| Market
Cap: |
30.69(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.5943 - $0.5943 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Genocea Biosciences is a biopharmaceutical company that discovers and develops cancer immunotherapies using its proprietary ATLAS™ platform. The ATLAS platform can profile each patient's CD4+ and CD8+ T cell immune responses to every potential target or antigen identified by sequencing of that patient's tumor. GEN-011 is an investigational solid tumor cell therapy candidate comprised of CD4+ and CD8+ neoantigen-targeted peripheral T cells. GEN-011 is comprised of T cells extracted from the patient's peripheral blood and specific for ATLAS-prioritized neoantigens. GEN-009 is an investigational neoantigen vaccine delivering adjuvanted synthetic long peptides from ATLAS-identified neoantigens.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
93,582,981 |
| Total Sell Value |
$0 |
$0 |
$0 |
$6,768,648 |
| Total People Sold |
0 |
0 |
0 |
15 |
| Total Sell Transactions |
0 |
0 |
0 |
27 |
| End Date |
2024-02-22 |
2023-11-21 |
2023-05-23 |
2022-05-23 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Glaxosmithkline Plc |
10% Owner |
– – • |
2019-06-24 |
4 |
B |
$3.50 |
$6,499,997 |
I/I |
1,857,142 |
3,365,884 |
1.5 |
- |
|
| Nea 16 Gp, Llc |
10% Owner |
– – • |
2019-06-24 |
4 |
B |
$3.50 |
$9,999,997 |
D/D |
2,857,142 |
7,225,676 |
2.45 |
- |
|
| Behbahani Ali |
Director |
– • • |
2019-06-24 |
4 |
B |
$3.50 |
$9,999,997 |
I/I |
2,857,142 |
7,225,676 |
2.25 |
- |
|
| Makhzoumi Mohamad |
10% Owner |
– – • |
2019-06-24 |
4 |
B |
$3.50 |
$9,999,997 |
I/I |
2,857,142 |
7,225,676 |
1.5 |
- |
|
| Barris Peter J |
10% Owner |
– – • |
2019-06-24 |
4 |
B |
$3.50 |
$9,999,997 |
I/I |
2,857,142 |
7,225,676 |
1.5 |
- |
|
| Chang Carmen |
10% Owner |
– – • |
2019-06-24 |
4 |
B |
$3.50 |
$9,999,997 |
I/I |
2,857,142 |
7,225,676 |
1.5 |
- |
|
| Florence Anthony A. Jr. |
10% Owner |
– – • |
2019-06-24 |
4 |
B |
$3.50 |
$9,999,997 |
I/I |
2,857,142 |
7,225,676 |
1.5 |
- |
|
| Sandell Scott D |
10% Owner |
– – • |
2019-06-24 |
4 |
B |
$3.50 |
$9,999,997 |
I/I |
2,857,142 |
7,225,676 |
1.5 |
- |
|
| Makower Joshua |
10% Owner |
– – • |
2019-06-24 |
4 |
B |
$3.50 |
$9,999,997 |
I/I |
2,857,142 |
7,225,676 |
1.5 |
- |
|
| Baskett Forest |
10% Owner |
– – • |
2019-06-24 |
4 |
B |
$3.50 |
$9,999,997 |
I/I |
2,857,142 |
7,225,676 |
1.5 |
- |
|
| Mott David M |
10% Owner |
– – • |
2019-06-24 |
4 |
B |
$3.50 |
$9,999,997 |
I/I |
2,857,142 |
7,225,676 |
1.5 |
- |
|
| Sonsini Peter W. |
10% Owner |
– – • |
2019-06-24 |
4 |
B |
$3.50 |
$9,999,997 |
I/I |
2,857,142 |
7,225,676 |
1.5 |
- |
|
| Singh Narinderjeet |
SENIOR VP, PS&M |
• – – |
2019-05-08 |
4 |
OE |
$0.54 |
$3,937 |
D/D |
7,291 |
61,873 |
|
- |
|
| Singh Narinderjeet |
SENIOR VP, PS&M |
• – – |
2019-04-11 |
4 |
OE |
$0.54 |
$3,937 |
D/D |
7,291 |
54,582 |
|
- |
|
| Singh Narinderjeet |
SENIOR VP, PS&M |
• – – |
2019-03-18 |
4 |
OE |
$0.54 |
$3,937 |
D/D |
7,291 |
47,291 |
|
- |
|
| Clark William D |
President and CEO |
• • – |
2019-03-15 |
4 |
OE |
$0.54 |
$8,100 |
D/D |
15,000 |
119,931 |
|
- |
|
| Glaxosmithkline Plc |
10% Owner |
– – • |
2019-02-14 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
12,069,937 |
|
- |
|
| Makower Joshua |
10% Owner |
– – • |
2019-02-14 |
4 |
B |
$0.47 |
$4,688,619 |
I/I |
9,948,269 |
34,948,269 |
1.5 |
- |
|
| Chang Carmen |
10% Owner |
– – • |
2019-02-14 |
4 |
B |
$0.47 |
$4,688,619 |
I/I |
9,948,269 |
34,948,269 |
1.5 |
- |
|
| Nea 16 Gp, Llc |
10% Owner |
– – • |
2019-02-14 |
4 |
B |
$0.47 |
$4,688,619 |
D/D |
9,948,269 |
34,948,269 |
2.45 |
- |
|
| Behbahani Ali |
Director |
– • • |
2019-02-14 |
4 |
B |
$0.47 |
$4,688,619 |
I/I |
9,948,269 |
34,948,269 |
2.25 |
- |
|
| Sonsini Peter W. |
10% Owner |
– – • |
2019-02-14 |
4 |
B |
$0.47 |
$4,688,619 |
I/I |
9,948,269 |
34,948,269 |
1.5 |
- |
|
| Sandell Scott D |
10% Owner |
– – • |
2019-02-14 |
4 |
B |
$0.47 |
$4,688,619 |
I/I |
9,948,269 |
34,948,269 |
1.5 |
- |
|
| Mott David M |
10% Owner |
– – • |
2019-02-14 |
4 |
B |
$0.47 |
$4,688,619 |
I/I |
9,948,269 |
34,948,269 |
1.5 |
- |
|
| Baskett Forest |
10% Owner |
– – • |
2019-02-14 |
4 |
B |
$0.47 |
$4,688,619 |
I/I |
9,948,269 |
34,948,269 |
1.5 |
- |
|
182 Records found
|
|
Page 4 of 8 |
|
|
